Research programme: proto oncogene proteins c-akt inhibitors - DeveloGen

Drug Profile

Research programme: proto oncogene proteins c-akt inhibitors - DeveloGen

Latest Information Update: 27 Sep 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DeveloGen
  • Class Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 02 Sep 2010 DeveloGen has been acquired by Evotec AG
  • 21 Jun 2007 Teva Pharmaceutical Industries granted an exclusive worldwide license to DeveloGen's protein kinase B technology for the treatment of cancer
  • 14 Jun 2004 Peptor has been acquired by, and merged into, DeveloGen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top